AbbVie Inc
USUSDAbbVie Inc (LSE:0QCV) — Biotechnology: Pharmaceutical Preparations. Numero di borse in cui sono quotate le azioni della società: 4. In questa pagina: prezzo e grafico, dividendi, principali azionisti e cronologia del numero di azioni.
Informazioni sull'Azienda
- Sito Web
- abbvie.com
- Settore
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sede Centrale
- North Chicago, United States
- Amministratore Delegato
- Robert A. Michael
- Dipendenti
- 57 000
- Fondata
- 2012
- Quotata dal
- 08.04.2013 (LSE:0QCV)
- Azioni in Circolazione
- Flottante
- 1.76 Mld
- Capitalizzazione di Mercato
- 470.55 Mld USD
- Insider
- 0.11%
- Investitori Istituzionali
- 77.37%
- Settore (SIC)
- Pharmaceutical Preparations
- Forma Giuridica
- XTIQ
- ISIN
- US00287Y1091
- LEI
- FR5LCKFTG8054YNNRU85
- P/E
- 39.5
- Payout Ratio
- 190%
- FCF
- 18.2 Mld USD
- Pagamenti / FCF
- 66%
- Debito
- 70.8 Mld USD3.5 anni di FCF
- Serie di Dividendi
- 13 a.
- Utili, FCF e dividendi pagati — per i 12 mesi fino a 30.06.2026 (l'ultimo rapporto dell'azienda).
- NAV
Descrizione
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Dividendi
AbbVie Inc (ABBV) paga dividendi trimestralmente. All'anno (12 mesi fino all'ultimo pagamento annunciato): 6.92 USD per azione (pagamenti: 4). Questo rappresenta circa il 2.44% del prezzo attuale delle azioni. In base alla storia dei pagamenti, la prossima data ex-dividendo è prevista intorno al 14.01.2027. Storia dei dividendi ininterrotta: 13 anni.
| Data Ex | Pagamento | Importo | % | Tipo | Ticker |
|---|---|---|---|---|---|
| 2026-10-15 | 2026-11-16 | 1.7300 USD | 0.6/2.4 % | trimestrale | US:ABBV |
| 2026-07-15 | 2026-08-14 | 1.7300 USD | 0.7/2.8 % | trimestrale | US:ABBV |
| 2026-04-15 | 2026-05-15 | 1.7300 USD | 0.8/3.2 % | trimestrale | US:ABBV |
| 2026-01-16 | 2026-02-17 | 1.7300 USD | 0.8/3.1 % | trimestrale | US:ABBV |
| 2025-10-15 | 2025-11-14 | 1.6400 USD | 0.7/2.9 % | trimestrale | US:ABBV |
| 2025-07-15 | 2025-08-15 | 1.6400 USD | 0.9/3.4 % | trimestrale | US:ABBV |
| 2025-04-15 | 2025-05-15 | 1.6400 USD | 0.9/3.6 % | trimestrale | US:ABBV |
| 2025-01-15 | 2025-02-14 | 1.6400 USD | 0.9/3.6 % | trimestrale | US:ABBV |
| 2024-10-15 | 2024-11-15 | 1.5500 USD | 0.8/3.2 % | trimestrale | US:ABBV |
| 2024-07-15 | 2024-08-15 | 1.5500 USD | 0.5/2.2 % | trimestrale | US:ABBV |
| 2024-04-12 | 2024-05-15 | 1.5500 USD | 0.5/≈2.2 % | trimestrale | US:ABBV |
| 2024-01-12 | 2024-02-15 | 1.5500 USD | 0.5/≈2.2 % | trimestrale | US:ABBV |
| 2023-10-12 | 2023-11-15 | 1.4800 USD | 0.5/≈2.1 % | trimestrale | US:ABBV |
Notizie di Questa Settimana
Comunicati stampa dal sito web per investitori della società, aggiornati quotidianamente. I link conducono al sito web dell'azienda. I titoli sono nella lingua originale, come sul sito web dell'azienda.
Principali Azionisti
| Detentore | Quota | Azioni | Data del Rapporto |
|---|---|---|---|
| BlackRock | 8.46% | 149.49 Mln | 2026-06-30 |
| Vanguard Capital Managem… | 6.53% | 115.4 Mln | 2026-06-30 |
| State Street Corporation | 4.67% | 82.6 Mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 56.09 Mln | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.74% | 48.48 Mln | 2026-06-30 |
| JPMORGAN CHASE & CO | 2.71% | 47.86 Mln | 2026-06-30 |
| Geode Capital Management… | 2.66% | 47 Mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 45.78 Mln | 2026-06-30 |
| Morgan Stanley | 2.2% | 38.9 Mln | 2026-06-30 |
| Capital Research Global… | 1.7% | 30.1 Mln | 2026-06-30 |
| NORGES BANK | 1.45% | 25.55 Mln | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 23.84 Mln | 2026-08-31 |
| Fidelity Concord Street… | 1.29% | 22.85 Mln | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 21.61 Mln | 2026-08-31 |
| Bank of America Corporat… | 1.2% | 21.24 Mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 16.82 Mln | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 12.7 Mln | 2026-08-31 |
| AMERICAN MUTUAL FUND | 0.63% | 11.15 Mln | 2026-07-31 |
| Capital Income Builder | 0.57% | 10.06 Mln | 2026-07-31 |
| VANGUARD SPECIALIZED FUN… | 0.57% | 10 Mln | 2026-07-31 |
| GONZALEZ RICHARD A (Dire… | ≈0.02% | 386 479 | 2025-03-31 |
| SALEKI-GERHARDT AZITA (C… | ≈0.01% | 220 682 | 2026-02-18 |
| MICHAEL ROBERT A. (Chief… | ≈0.01% | 215 260 | 2026-02-18 |
| FREYMAN THOMAS C (Direct… | ≈0.01% | 135 751 | 2026-05-08 |
| STEWART JEFFREY RYAN (Of… | ≈0.01% | 108 321 | 2026-02-18 |
| DONOGHOE NICHOLAS (Offic… | ≈0% | 74 430 | 2026-08-14 |
| REENTS SCOTT T. (Chief F… | ≈0% | 60 415 | 2026-02-18 |
| THAKKAR ROOPAL (Officer) | ≈0% | 60 413 | 2026-02-18 |
| TILTON GLENN FLETCHER (D… | ≈0% | 51 914 | 2025-05-09 |
| RAPP EDWARD J (Director) | ≈0% | 45 964 | 2026-05-08 |
| The Vanguard Group | — | — | — |
